| Literature DB >> 29208986 |
Bruna Corradetti1,2, Francesca Taraballi3,4, Claudia Corbo3,5, Fernando Cabrera3, Laura Pandolfi3, Silvia Minardi3, Xin Wang3, Jeffrey Van Eps3, Guillermo Bauza3,4,6, Bradley Weiner4, Ennio Tasciotti7,8,9.
Abstract
In mammals, tissue regeneration is accomplished through a well-regulated, complex cascade of events. The disruption of the cellular and molecular processes involved in tissue healing might lead to scar formation. Most tissue engineering approaches have tried to improve the regenerative outcome following an injury, through the combination of biocompatible materials, stem cells and bioactive factors. However, implanted materials can cause further healing impairments due to the persistent inflammatory stimuli that trigger the onset of chronic inflammation. Here, it is described at the molecular, cellular and tissue level, the body response to a functionalized biomimetic collagen scaffold. The grafting of chondroitin sulfate on the surface of the scaffold is able to induce a pro-regenerative environment at the site of a subcutaneous implant. The early in situ recruitment, and sustained local retention of anti-inflammatory macrophages significantly reduced the pro-inflammatory environment and triggered a different healing cascade, ultimately leading to collagen fibril re-organization, blood vessel formation, and scaffold integration with the surrounding native tissue.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29208986 PMCID: PMC5717048 DOI: 10.1038/s41598-017-16895-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1(A) Photograph of the collagen (CL)-chondroitin sulfate modified scaffold (CSCL). (B) Carbodiimide chemistry schematic to covalent link the chondroitin sulfate to Collagen structure. The carboxylic acid presented on CS sequence forms an amide bond with the free primary amines present on the collagen sequence. (C) SEM images showing scaffold’s porosity (on the left site) and the intact nanostructure of the collagen fibers (on the right site). (Scale bars: 100 μm and 500 nm). (D) Pictures showing the subcutaneous implant procedure.
Figure 2Infiltrating cells after 1 day from implantation in CSCL scaffold. (A) Representative SEM images showing the CSCL scaffold’ surface completely covered by cells in two different magnifications (scale bars: 200 μm and 100 μm). (B) Total number of cells recovered by CSCL and CL counted by flow cytometry. Graph represents mean values ± SD (n = 3). (C) SEM magnification to evaluate the infiltrating cells morphology on CSCL (scale bar: 10 μm). (D) Masson’s stained section revealed a massive infiltration of cells through the entire CSCL’ thickness coming from the surrounding vasculature (inset). (Scale bar: 200 μm). (E) Magnification Masson’s stained section (on the left) and a SEM image (on the right) highlighted a high level of fibronectin on the CSCL surface (yellow arrows) (scale bars: 40 μm and 15 μm, respectively). (F) Evaluation of fibronectin level of expression was performed on protein extracts from CL and CSCL scaffolds. Densitometric analysis, y-axis shows the optical density of protein expression (A) normalized against the control (B, GAPDH). Results are shown as means of three replicates ± SD. ** p ≤ 0.001.
Figure 3Characterization of infiltrating cells at day 1 post implant. (A) Heatmap of differentially expressed genes (DE) between CSCL and CL in in vivo explants from inflammatory cytokines and receptors PCR array. Expression levels of DE genes are displayed as color-coded: red represents over expression while green under-expression. Gene ontology analysis on over-expressed genes in CSCL shows that among the statistically significant pathways involving our data set of proteins, we found “regulation of macrophages chemotaxis” (p-value: 5.9E-18). (B) Rat cytokines/chemokines profiling of proteins adsorbed onto CL and CSCL scaffolds 1d after implant. Densitometric analysis. Results are shown as mean of three replicates ± SD. **p ≤ 0.001. CINC-1, CINC-3 and MIP-3α revealed different levels of abundance. (C) Percentage of macrophages (anti-macrophages +/anti-CD45 + cells) and other leukocytes (CD45 + cells) isolated from explants and assessed by flow cytometry. Graph represents mean values ± SD (n = 3). (D) Quantification of immunofluorescence staining for IL-10, iNOS and CD206 positive cells on consecutive sections Graph represents mean values ± SD (n = 10). (E) Representative immunofluorescence stained consecutive sections with anti-IL-10 (purple) and anti-CD206 (green) and anti-iNOS (red). The images show presence of macrophages IL-10+ (purple) within the scaffold 1-day post implant (scale bars: 50 μm).
Over- and under-expressed genes in 24 h CSCL in vivo implant compared with CL profiled on pro-inflammatory cytokines and receptors PCR array.
| Symbol | Refseq | Description | Fold Change | p-value |
|---|---|---|---|---|
|
| ||||
| Aimp1 | NM_053757 | Aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 | 2,0423 | 0,034437 |
| Ccl12 | NM_001105822 | Chemokine (C-C motif) ligand 12 | 3,5857 | 0,013407 |
| Ccl2 | NM_031530 | Chemokine (C-C motif) ligand 2 | 2,6097 | 0,053334 |
| Ccl5 | NM_031116 | Chemokine (C-C motif) ligand 5 | 2,1609 | 0,07928 |
| Ccr1 | NM_020542 | Chemokine (C-C motif) receptor 1 | 2,5869 | 0,001323 |
| Ccr2 | NM_021866 | Chemokine (C-C motif) receptor 2 | 3,147 | 0,008204 |
| Ccr4 | NM_133532 | Chemokine (C-C motif) receptor 4 | 2,1166 | 0,253888 |
| Ccr6 | NM_001013145 | Chemokine (C-C motif) receptor 6 | 3,2838 | 0,050775 |
| Ccr8 | XM_236704 | Chemokine (C-C motif) receptor 8 | 3,4874 | 0,005749 |
| Cx3cl1 | NM_134455 | Chemokine (C-X3-C motif) ligand 1 | 2,0435 | 0,011638 |
| Cxcl11 | NM_182952 | Chemokine (C-X-C motif) ligand 11 | 2,406 | 0,027316 |
| Cxcl9 | NM_145672 | Chemokine (C-X-C motif) ligand 9 | 2,0105 | 0,06048 |
| Cxcr5 | NM_053303 | Chemokine (C-X-C motif) receptor 5 | 3,0484 | 0,001469 |
| Faslg | NM_012908 | Fas ligand (TNF superfamily, member 6) | 2,9559 | 0,002851 |
| Il1r1 | NM_013123 | Interleukin 1 receptor, type I | 3,3212 | 0,034378 |
| Il21 | NM_001108943 | Interleukin 21 | 2,5714 | 0,130204 |
| Il3 | NM_031513 | Interleukin 3 | 3,4003 | 0,028243 |
| Il33 | NM_001014166 | Interleukin 33 | 2,2283 | 0,205627 |
| Il4 | NM_201270 | Interleukin 4 | 2,4614 | 0,046653 |
| Il5ra | NM_053645 | Interleukin 5 receptor, alpha | 2,3901 | 0,009556 |
| Il6r | NM_017020 | Interleukin 6 receptor | 2,478 | 0,004808 |
| Il6st | NM_001008725 | Interleukin 6 signal transducer | 2,2308 | 0,001629 |
| Il7 | NM_013110 | Interleukin 7 | 3,5534 | 0,000298 |
| Lta | NM_080769 | Lymphotoxin alpha (TNF superfamily, member 1) | 2,9841 | 0,025761 |
| Spp1 | NM_012881 | Secreted phosphoprotein 1 | 2,3364 | 0,109091 |
| Tnfrsf11b | NM_012870 | Tumor necrosis factor receptor superfamily, member 11b | 3,33 | 0,172409 |
|
| ||||
| Il11 | NM_133519 | Interleukin 11 | 0,2471 | 0,226938 |
| Il1a | NM_017019 | Interleukin 1 alpha | 0,1181 | 0,009542 |
| Il2rg | NM_080889 | Interleukin 2 receptor, gamma | 0,3161 | 0,349324 |
| Tnfsf14 | NM_001191803 | Tumor necrosis factor (ligand) superfamily, member 14 | 0,1531 | 0,011446 |
Figure 4Switching off of inflammation. (A) Representative images of Masson’s stained sections of CSCL (dotted yellow lines mark the interface with the native tissue) at 3 (top) and 7 days (bottom) (Scale bars: 100 μm, 50 μm). Images highlight dampen of the inflammation representing in a decrease of infiltrating cells from the surrounding tissue and an augment of extracellular matrix deposition. (B) Reduction in the number of cells harvested from explanted CSCL at 3 and 7 days. Values are mean ± SD (n = 3) (n = 3, **p < 0.01). (C) Representative immunofluorescence consecutive sections showing anti (IL-10)- and pro(iNOS)- inflammatory markers. Cells are counterstained with anti-Macrophages antibody. A progressive reduction of IL-10+ and iNos+ macrophages between 3 and 7 days is shown (scale bars 50 μm). (D) Flow cytometric analysis shows the percentage of IL10+/CD206+ macrophages at 3 and 7 days from CSCL implant.
Figure 5Inflammatory proteins expression induced by CSCL. (A) Differences in the rat cytokines/chemokines profiling of CSCL at 3 days and 7 days. Proteins adsorbed on CSCL surface were extracted. Proteins with different levels of abundance at 3 and 7 days are represented. Bar graph presents mean densitometry units of each spot. Values are presented as the mean ± SD. (B) Quantitative PCR analysis for the pro-inflammatory (Il-6, Tnf-α Il-1β, iNos)- associated markers at 3 and 7 days from CSCL implants. Expression levels normalized to the reference gene (Gapdh). Data are represented as fold-change compared with expression observed in subcutaneous tissues explanted from rats in absence of inflammation. Values are mean ± SD (n = 3). Asterisks depict significant differences between 3 and 7 days (**p < 0.01).
Figure 6Scaffold integration. (A) Representative Masson’s trichromic stained whole section shows the different integration of the scaffold along all its cross-section between CL and CSCL (1 mm). (B) Representative Masson’s trichromic stained whole section shows the complete integration of the scaffold along all its cross-section (Scale bars: 100 μm). Arrows indicate the vessels inside the scaffold. The graph indicates the presence of the vessels throughout the scaffolds’ thickness (distributed in the 3 areas) (n = 3, *p < 0.05). (C) Representative CD31 immunofluorescence stained section used for quantification (scale bars: 20 μm). (D) Quantification of CD31 immunofluorescence stained section (n = 3, *p < 0.05). (E) SEM image of the scaffold surface shows completely remodeling of the scaffold (Scale bar: 10 μm).
List of genes found over-expressed among the 84 tested through the wound healing PCR array in 21 d CSCL in vivo implant compared to CL.
| Symbol | Refseq | Description | Fold Change | 95% CI |
|---|---|---|---|---|
| Pten | NM_031606 | Phosphatase and tensin homolog | 6,09 | (0.00001, 19.52) |
| Csf2 | NM_053852 | Colony stimulating factor 2 (granulocyte-macrophage) | 5,24 | (0.00001, 23.34) |
| Col1a1 | NM_053304 | Collagen, type I, alpha 1 | 5,22 | (0.00001, 14.46) |
| Csf3 | NM_017104 | Colony stimulating factor 3 (granulocyte) | 5,02 | (0.00001, 23.34) |
| Pdgfa | NM_012801 | Platelet-derived growth factor alpha polypeptide | 4,93 | (0.00001, 20.54) |
| Col1a2 | NM_053356 | Collagen, type I, alpha 2 | 4,05 | (0.00001, 15.35) |
| Ccl7 | NM_001007612 | Chemokine (C-C motif) ligand 7 | 3,79 | (0.00001, 14.17) |
| Hbegf | NM_012945 | Heparin-binding EGF-like growth factor | 3,66 | (0.00001, 16.11) |
| Wisp1 | NM_031716 | WNT1 inducible signaling pathway protein 1 | 3,58 | (0.00001, 17.13) |
| Ctnnb1 | NM_053357 | Catenin (cadherin associated protein), beta 1 | 3,20 | (0.00001, 13.95) |
| Itga3 | NM_001108292 | Integrin, alpha 3 | 3,17 | (0.00001, 13.52) |
| Plg | NM_053491 | Plasminogen | 3,15 | (0.00001, 12.00) |
| Col5a2 | NM_053488 | Collagen, type V, alpha 2 | 3,11 | (0.00001, 11.58) |
| Ctsg | NM_001106041 | Cathepsin G | 2,95 | (0.00001, 9.59) |
| Cxcl1 | NM_030845 | Chemokine (C-X-C motif) ligand 1 | 2,69 | (0.00001, 10.77) |
| Col3a1 | NM_032085 | Collagen, type III, alpha 1 | 2,61 | (0.00001, 9.05) |
| Fga | NM_001008724 | Fibrinogen alpha chain | 2,53 | (0.00001, 9.22) |
| Col14a1 | NM_001130548 | Collagen, type XIV, alpha 1 | 2,48 | (0.00001, 9.11) |
| Vtn | NM_019156 | Vitronectin | 2,47 | (0.00001, 8.03) |
| Timp1 | NM_053819 | TIMP metallopeptidase inhibitor 1 | 2,41 | (0.00001, 8.42) |
| Ccl12 | NM_001105822 | Chemokine (C-C motif) ligand 12 | 2,36 | (0.00001, 9.91) |
| Fgf7 | NM_022182 | Fibroblast growth factor 7 | 2,29 | (0.00001, 8.14) |
| Igf1 | NM_178866 | Insulin-like growth factor 1 | 2,26 | (0.00001, 6.91) |
| Cxcl5 | NM_022214 | Chemokine (C-X-C motif) ligand 5 | 2,26 | (0.00001, 8.34) |
| Vegfa | NM_031836 | Vascular endothelial growth factor A | 2,25 | (0.00001, 7.93) |
| F3 | NM_013057 | Coagulation factor III (thromboplastin, tissue factor) | 2,17 | (0.00001, 7.43) |
| Ifng | NM_138880 | Interferon gamma | 2,12 | (0.00001, 6.74) |
| Ctgf | NM_022266 | Connective tissue growth factor | 2,07 | (0.00001, 6.23) |
Figure 7Differential genetic profile induced by CSCL at 21 days. Functional classification of over-expressed genes in CSCL in vivo implants from wound healing PCR array by using GENEMANIA web analysis tool.
Figure 8Schematic description of the regenerative events induced by the CS functionalization (hard line). The presence of CS results in the anticipated occurrence and shorter duration of the cascade of events following scaffold implantation. The dotted line shows the established wound healing phases.